Invest A/s Lundbeckfond - 09 Nov 2021 Form 4 Insider Report for IO Biotech, Inc. (IOBT)

Role
10%+ Owner
Signature
Lundbeckfond Invest A/S, by: /s/ Brian Burkavage, Attorney-in-Fact for Christian Elling, Managing Partner, and Lene Skole, Chief Executive Officer
Issuer symbol
IOBT
Transactions as of
09 Nov 2021
Net transactions value
+$29,999,998
Form type
4
Filing time
12 Nov 2021, 15:15:46 UTC
Previous filing
04 Nov 2021
Next filing
11 Aug 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IOBT Common Stock Conversion of derivative security +2,014,161 2,014,161 09 Nov 2021 Direct F1
transaction IOBT Common Stock Conversion of derivative security +1,892,434 +94% 3,906,595 09 Nov 2021 Direct F2
transaction IOBT Common Stock Purchase $29,999,998 +2,142,857 +55% $14.00* 6,049,452 09 Nov 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IOBT Series B Preferred Stock Conversion of derivative security $0 -219,595 -100% $0.000000* 0 09 Nov 2021 Common Stock 2,014,161 Direct F1
transaction IOBT Series C Preferred Stock Conversion of derivative security $0 -150,534 -100% $0.000000* 0 09 Nov 2021 Common Stock 1,892,434 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series B Preferred Stock had no expiration date.
F2 Upon the closing of the IPO, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date.